NEW YORK, June 18 /PRNewswire/ -- Danube Pharmaceuticals, Inc., a privately held biopharmaceutical company specializing in the commercial research and development of innovative drugs for ophthalmology, is pleased to announce the appointment of Dr. Barrett Katz, MD, MBA as its Chief Executive Officer.
"I am honored and delighted to join Danube Pharmaceuticals at this inflection point in its history as it advances its lead programs through clinical trials and brings novel bench research to the clinics and bedside," said Barrett Katz, MD, MBA, Chief Executive Officer of Danube.
"We are delighted to welcome Dr. Katz to our team," said David R. Guyer, MD, Chairman of Danube. "His leadership, energy and experience will transform our senior management team and complement the clinical and managerial talents we have. His outstanding reputation in the international ophthalmology community coupled with his expertise in the field of drug development, drug approval and product launch will be invaluable for bringing Danube's product candidates from clinical trials to market effectively and efficiently."
Dr. Katz is a renowned ophthalmologist with over 25 years of experience in clinical trials and medical strategy, drug development and regulatory issues. Prior to joining Danube, Dr. Katz served as Executive Vice President and Chief Medical Officer of Fovea Pharmaceuticals SA, in Paris. Before that he was Vice President for Medical Affairs and Medical Strategy at Eyetech Pharmaceuticals, and had been integral to the team that developed Macugen(TM) and brought it to market.
Dr. Katz also served as Professor of Ophthalmology, Neurology and Neurosurgery, and as the Chairman of the Department of Ophthalmology at The George Washington University School of Medicine in Washington, D.C. While there, he formulated and sponsored a joint fellowship in Ophthalmology drug development, clinical trials, and regulatory affairs with the U.S. Food and Drug Administration. Dr. Katz served on the executive committee of the Optic Neuritis Treatment Trial, and has been an active participant and principle investigator of many multi-centre clinical trials.
Dr. Katz currently serves as Clinical Professor of Ophthalmology at New York University School of Medicine as well as at the Weill Medical College of Cornell University. Dr. Katz served as a fellow at Harvard University in Boston, the National Institutes of Health, The National Hospital at Queen's Square in London, and the University of California at San Francisco after completing residencies in Neurology at Harvard Medical School and in Ophthalmology at Tufts-New England Medical Center. He received his MD with honors from the Case Western Reserve University School of Medicine and his AB, magna cum laude, from Colgate University. He is the author of several hundred publications, and the recipient of over two dozen major research grants.
About Danube Pharmaceuticals, Inc.
Danube is a biopharmaceutical company dedicated to the research and development of treatments for diseases of the eye. Danube's lead compound DNB-001, is a small molecule for the treatment of glaucoma available in both oral and topical formulation. In preclinical studies DNB-001 has been shown through novel mechanisms of action to both lower intraocular pressure (IOP) and to provide direct neuroprotective benefits to the optic nerve and its retinal ganglion cells, providing a dual approach to glaucoma therapy not provided by any currently marketed product. DNB-001 has been tested in a Phase I clinical trial in Europe and is currently being studied in a Phase II clinical trial in Europe. For more information on Danube please visit http://www.danubepharma.com .
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, and product pricing and third party reimbursement. We undertake no obligation to update any forward-looking statement contained in this press release, except as required by law.
|SOURCE Danube Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved